FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ AutoinjectorWESTLAKE ...

SCHAUMBURG, Ill., March 20, 2024--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for ...

BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- ...

ELK GROVE VILLAGE, Ill., Oct. 21, 2024 /PRNewswire/ -- Orsini announced today that it has been chosen by scPharmaceuticals to distribute FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous ...

LEXINGTON, Mass., scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial. The trial in patients with heart failure ...

Hikma has launched furosemide injection, in 20mg/2ml, 40mg/4ml, 100mg/10ml, 500mg/50ml and 1,000mg/100ml presentations. “Hikma is introducing the first FDA approved 50ml and 100ml presentations to the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...